Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18342602 
Ozcan U, et al. (2008) Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29, 541-51 18342602
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S52-p - eIF2-alpha (human)
Orthologous residues
eIF2‑alpha (human): S52‑p, eIF2‑alpha (mouse): S52‑p, eIF2‑alpha (rat): S52‑p, eIF2‑alpha (rabbit): S51‑p, eIF2‑alpha (fruit fly): S51‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse

S235-p - S6 (human)
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse

S236-p - S6 (human)
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse

S52-p - eIF2-alpha (mouse)
Orthologous residues
eIF2‑alpha (human): S52‑p, eIF2‑alpha (mouse): S52‑p, eIF2‑alpha (rat): S52‑p, eIF2‑alpha (rabbit): S51‑p, eIF2‑alpha (fruit fly): S51‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease

S63-p - Jun (mouse)
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TSC2 (mouse) increase homozygous null
rapamycin TSC2 (mouse) inhibit treatment-induced increase
butyrate TSC2 (mouse) inhibit treatment-induced increase

T412-p - p70S6K (mouse)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TSC1 (mouse) increase homozygous null
rapamycin TSC1 (mouse) inhibit treatment-induced increase
butyrate TSC1 (mouse) inhibit treatment-induced increase
TSC2 (mouse) increase homozygous null
rapamycin TSC2 (mouse) inhibit treatment-induced increase
butyrate TSC2 (mouse) inhibit treatment-induced increase
rapamycin decrease

T980-p - PERK (mouse)
Orthologous residues
PERK (human): T982‑p, PERK (mouse): T980‑p, PERK (rat): T974‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TSC1 (mouse) increase homozygous null
rapamycin TSC1 (mouse) inhibit treatment-induced increase
butyrate TSC1 (mouse) inhibit treatment-induced increase
TSC2 (mouse) increase homozygous null
rapamycin TSC2 (mouse) inhibit treatment-induced increase
butyrate TSC2 (mouse) inhibit treatment-induced increase
rapamycin decrease

S235-p - S6 (mouse)
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TSC1 (mouse) increase homozygous null
rapamycin TSC1 (mouse) inhibit treatment-induced increase
butyrate TSC1 (mouse) inhibit treatment-induced increase
TSC2 (mouse) increase homozygous null
rapamycin TSC2 (mouse) inhibit treatment-induced increase
butyrate TSC2 (mouse) inhibit treatment-induced increase

S236-p - S6 (mouse)
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  kidney cancer, liver cancer, tuberous sclerosis
 Relevant cell lines - cell types - tissues:  glial, kidney, liver, MEF (fibroblast)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TSC1 (mouse) increase homozygous null
rapamycin TSC1 (mouse) inhibit treatment-induced increase
butyrate TSC1 (mouse) inhibit treatment-induced increase
TSC2 (mouse) increase homozygous null
rapamycin TSC2 (mouse) inhibit treatment-induced increase
butyrate TSC2 (mouse) inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.